Abstract
Around 2000 children are born in the UK per year with a neurodevelopmental genetic syndrome with significantly increased morbidity and mortality(1). Often little is known about expected growth and phenotypes in these children. Parents have responded by setting up social media groups to generate data themselves. Given the significant clinical evidence gaps, this research will attempt to identify growth patterns, developmental profiles and phenotypes, providing data on long-term medical and educational outcomes. This will guide clinicians when to investigate, monitor or treat symptoms and when to search for additional or alternative diagnoses.
Methods and analysis This is an observational, multicentre cohort study recruiting between March 2023 and February 2026. Children aged 6 months up to 16 years with a pathogenic or likely pathogenic variant in a specified gene will be eligible. Children will be identified through the NHS and via self-recruitment. Parents or carers will complete a questionnaire at baseline and again one year after recruitment. The named clinician (in most cases a clinical geneticist) will complete a clinical proforma which will provide data from their most recent clinical assessment. Qualitative interviews will be undertaken with a subset of parents partway through the study. Growth and developmental milestone curves will be generated through the DECIPHER website (https://deciphergenomics.org) where 5 or more children have the same genetic syndrome (at least ten groups expected).
The results will be presented at national and international conferences concerning the care of children with genetic syndromes. Results will also be submitted for peer review and publication.
Article Summary Strengths and Limitations of this study
This study is a collaborative effort which combines previous data with that of a large cohort to maximise possible outputs through the DECIPHER database.
The study is the first of its kind to acquire natural history clinical data from a large cohort across the UK to ascertain both gene specific data but also cross syndrome cohort metrics.
The study utilises the Musketeers Memorandum to facilitate recruitment from genetics centres across the UK and also empowers families to volunteer directly which will be supported by a national patient support charity.
This study does not recruit individuals over the age of 15 and so longer-term outcomes will not be evaluated. Further studies of older individuals will be required to gather their data and we hope that a follow-on study would be possible to enable this.
Data are largely gathered through online questionnaires completed by both parent and clinician. The quality of data received will vary depending on the user. This method of data collection may result in selection bias against certain demographic groups which will need to be accounted for in any discussion regarding the generalisability of the results.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DECIPHER is hosted by EMBL-EBI and funding for the DECIPHER project was provided by the Wellcome Trust [grant number WT223718/Z/21/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. KL and GenROC is supported by the National Institute for Health and Care Research Doctoral Research Fellowship 302303: The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript is based on Protocol V.7.0 dated 06/02/2023. The study received East Midlands - Nottingham Research Ethics Committee (REC) approval on 15 December 2022 and Health Research Authority approval on 9 February 2023. The study will be conducted in accordance with the protocol, NIHR Good Clinical Practice (14) and the principles of the Declaration of Helsinki. Any amendments of the protocol will be submitted to the REC for approval. On request, the study investigators and their institutions will permit study-related audits by the sponsor and relevant research ethics committee by providing direct access to source data. The University of Bristol holds the relevant insurance for this study and is the nominated sponsor for this study. A stakeholder group has been set up including clinical and laboratory geneticists and representatives from Unique and the Genomic Alliance. The stakeholder group provides advice to the investigators on all aspects of the study including aspects of safety and monitoring of serious adverse events. The DECIPHER project was given a favourable NRES REC opinion by Cambridge South (previously Cambridgeshire 4 REC), REC reference 04/MRE05/50, in November 2004. DECIPHER submits annual progress reports to ensure this favourable opinion applies for the duration of the research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
As this is a protocol paper there is no data requiring repository.
